Compare Invesco DB Agriculture Fund (DBA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Incyte Corporation — how do they compare? Invesco DB Agriculture Fund trades at $27.97, while Incyte Corporation trades at $115.26 (market cap $22.95B). The key difference: Incyte Corporation is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| DBA | INCY | |
|---|---|---|
52-Week High | $28.73 | $118.52 |
52-Week Low | $25.44 | $67.38 |
Market Cap | — | $22.95B |
Sector | — | Health |
Enterprise Value | — | $18.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund) trades at $27.72, down 0.18% with a bullish technical signal supported by moving averages. The ETF tracks agricultural commodities including corn, soybeans, and livestock. Recent news highlights supply disruptions in Brazil's coffee harvest and China's $17 billion U.S. crop purchase commitment through 2028, potentially benefiting agricultural ETFs.
The fund offers exposure to rising commodity prices driven by supply constraints and geopolitical factors, but faces volatility from weather patterns and global demand shifts. Key risks include commodity price fluctuations and concentrated agricultural exposure. Analyst sentiment is mixed with technical indicators showing strength but overbought conditions on shorter-term RSI.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
